YKL‐40 is a proposed biomarker of inflammation and remodelling elevated in children with bronchopulmonary dysplasia compared to asthma.

YKL-40 is a proposed biomarker of inflammation and remodelling elevated in children with bronchopulmonary dysplasia compared to asthma Keywords: asthma; biomarker; bronchopulmonary dysplasia; YKL-40 EN asthma biomarker bronchopulmonary dysplasia YKL-40 641 642 2 01/23/21 20210201 NES 210201 YKL-40 is a chitinase-like, secreted glycoprotein associated with several respiratory disorders, including asthma and oxidant-induced lung injuries.1 Its biological role remains unclear, but it correlates with markers of airway fibrosis and remodelling in asthma, where it has emerged as a candidate biomarker for non-type 2 inflammation.2 Bronchopulmonary dysplasia (BPD) is a chronic disorder, characterised by underdeveloped, damaged lungs following premature birth and mechanical ventilation, whereas asthma is a chronic inflammatory disease, often associated with atopy and reversibility in children.3 BPD has been associated with more airway fibrosis and non-reversible lung function impairment than asthma. YKL-40 could be useful in distinguishing asthma from BPD and could also indicate the degree of airway dysfunction in BPD. [Extracted from the article]